eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 15
Clinical research

Serum lipid metabolism in psoriasis and psoriatic arthritis – an update

Aldona Pietrzak, Paweł Chabros, Ewelina Grywalska, Paweł Kiciński, Kinga Franciszkiewicz-Pietrzak, Dorota Krasowska, Grzegorz Kandzierski

Arch Med Sci 2019; 15, 2: 369–375
Online publish date: 2018/03/08
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Psoriasis and psoriatic arthritis (PSA) are chronic, inflammatory, systemic diseases characterized by metabolic abnormalities, including an increased cardiovascular risk and an oxidative imbalance. This study assessed blood parameters of lipid metabolism and markers of oxidative stress in patients with psoriasis and PSA.

Material and methods
The study included 93 patients with psoriasis (31 patients with PSA and psoriasis, 62 patients with psoriasis vulgaris), and 60 healthy, age-matched controls. Serum concentrations of the glucose and the following lipid metabolism parameters were measured: triglycerides (TG), total cholesterol (TC), low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), high-density lipoproteins (HDL), and apolipoproteins A and B (ApoA, ApoB). Oxidative status was determined as serum concentrations of ox-LDL/MDA Adduct. The Psoriasis Area and Severity Index (PASI) was used to determine disease severity.

Among the three studied groups, controls had the highest HDL concentration (p < 0.001), patients with PSA had the highest ApoB concentration (p < 0.05), ApoA : ApoB ratio (p < 0.05), ox-LDL/MDA adduct concentration (p < 0.001), and TC: HDL and LDL : HDL ratios (accordingly p < 0.05, p < 0.01). In patients with psoriasis or PSA, oxidative status correlated positively with TC and ApoB concentrations.

In line with previous research, among patients with psoriasis and PSA, we found lipid metabolism abnormalities and an oxidative imbalance, which might be due to chronic inflammation in these conditions. Effective treatment of patients with psoriasis or PSA could reduce the risk of cardiovascular diseases.


oxidative stress, cholesterol, apolipoprotein, lipid metabolism

Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-9.
Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovascular risk factors a 12-week follow-up study. Am J Clin Dermatol 2010; 11: 423-32.
Bańska-Kisiel K, Haberka M, Bergler-Czop B, Brzezinska-Wcislo L, Okopień B, Gąsior Z. Carotid intima-media thickness in patients with mild or moderate psoriasis. Adv Dermatol Allergol 2016; 35: 286-9.
Raciborski F, Śliwczyński A, Kłak A, Kwiatkowska B, Brzozowska M, Tłustochowicz M. Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland. Reumatologia 2016; 54: 278-84.
Kaur S, Kingo K, Zilmer M. Psoriasis and cardiovascular risk – do promising new biomarkers have clinical impact? Mediators Inflamm 2017; 2017: 7279818.
Kucharz EJ, Stajszczyk M, Batko B, et al. Application of secukinumab in management of patients with psoriatic arthritis a standpoint of the Polish Society for Rheumatology and Polish Society of Dermatology. Forum Reumatol 2017; 3: 119-25.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957-70.
Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 78454.
Gentile M, Peluso R, Di Minno MN, et al. Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clin Rheumatol 2016; 35: 2023-9.
Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-22.
He L, Qin S, Dang L, et al. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. Biochim Biophys Acta 2014; 1841: 1709-15.
Vanaclocha F, Belincho I, Sanchez-Carazo J, et al. Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. Eur J Dermatol 2014; 24: 662-9.
Kawalec P, Malinowski K, Pilc A. Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatol Int 2016; 36: 1223-30.
Uczniak S, Gerlicz ZA, Kozłowska M, Kaszuba A. Presence of selected metabolic syndrome components in patients with psoriasis vulgaris. Postep Dermatol Alergol 2016; 33: 114-9.
Oh EH, Ro YS, Kim JE. Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study. J Dermatol 2017; 44: 621-9.
Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000; 59: 904-9.
Pietrzak A, Chodorowska G, Szepietowski J, Zalewska-Janowska A, Krasowska D, Hercogová J. Psoriasis and serum lipid abnormalities. Dermatol Ther 2010; 23: 160-73.
Paiva-Lopes M, Alves D. Psoriasis-associated vascular disease: the role of HDL. J Biomed Sci 2017; 24: 73.
Banach M, Jankowski P, Jóźwiak J, et al. PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016. Arch Med Sci 2017; 13: 1-45.
Štulc T, Lánská V, Šnejdrlová M, Vrablík M, Prusíková M, Češka R. A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Arch Med Sci 2017; 13: 705-10.
Vulic D, Loncar S, Ostojic M, et al. Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/Republic of Srpska/Bosnia and Herzegovina. Arch Med Sci 2016; 12: 736-41.
Dobiásová M, Frohlich JL. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apob-lipoprotein-depleted plasma (FER). Clin Biochem 2001; 34: 583-8.
Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36: 203-9.
Gerdes S, Osadtschy S, Buhles N, Baurecht H, Mrowietz U. Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol 2014; 23: 322-5.
Gkalpakiotis S, Arenbergerova M, Gkalpakioti P. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study. J Dermatol 2017; 44: 363-9.
Melczer N. Etiology and pathogenesis of psoriasis vulgaris. Cesk Dermatol 1963; 38: 337-40.
Orgaz-Molina J, Buendıa-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients with and without arthritis. J Am Acad Dermatol 2013; 69: 938-46.
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. Int J Dermatol 2015; 54: 442-5.
Batuca JR, Ames PRJ, Amaral M, Favas C, Isenberg DA, Delgado AJ. Antiatherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology 2009; 48: 26-31.
Batuca J, Lamy M, Neves M, et al. Anti-apolipoprotein A-I (ApoA-I) antibodies have different target epitopes in different clinical conditions. Atherosclerosis 2017; 263: 216-7.
Paiva-Lopes MJ, Batuca JR, Gouveia S, Faleiro I, Alves JD. Antibodies towards high density lipoproteins components in patients with psoriasis. J Invest Dermatol 2015; 135: S25.
Sunitha S, Rajappa M, Thappa DM, Chandrashekar L, Munisamy M, Revathy G. Is the ratio of antibodies against oxidized LDL to oxidized LDL an indicator of cardiovascular risk in psoriasis? Oman Med J 2016; 31: 390-3.
Flisiak I, Klepacki A, Chodynicka B. Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006; 11: 194-200.
Kato T, Terui T, Takematsu H, Tagami H. Effects of psoriatic scale extracts on oxidative metabolic responses in granulocytes assessed by chemiluminescence. Inflammation 1989; 13: 59-66.
Wiedow O, Young JA, Davison D, Christophers E. Antileukoprotease in psoriatic scales. J Invest Dermatol 1993; 101: 305-9.
Mrowietz U, Koch WA, Zhu K, et al. Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. Exp Dermatol 2001; 10: 238-45.
Oliviero F, Sfriso P, Baldo G, et al. Apolipoprotein A-1 and cholesterol in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 79-83.
Carlsohn A, Rohn S, Mayer F, Schweigert F. Physical activity, antioxidant status, and protein modification in adolescent athletes. Med Sci Sports Exerc 2010; 42: 1131-9.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe